Marex Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Marex Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$276K	Buy	+4,823	New	+$264K	﹤0.01%	894
2026 Q1	–	Sell	-74,314	Closed	-$4.42M	–	1039
2025 Q4	$4.42M	Buy	74,314 +47,824	+181%	+$2.6M	0.03%	230
2025 Q3	$1.43M	Buy	26,490 +12,762	+93%	+$730K	0.01%	298
2025 Q2	$755K	Buy	+13,728	New	+$808K	0.01%	322
2024 Q2	–	Sell	-7,778	Closed	-$679K	–	639
2024 Q1	$679K	Buy	7,778 +3,709	+91%	+$332K	0.02%	217
2023 Q4	$392K	Sell	4,069 -3,952	-49%	-$350K	0.02%	344
2023 Q3	$710K	Sell	8,021 -3,462	-30%	-$308K	0.1%	91
2023 Q2	$995K	Buy	+11,483	New	+$1.08M	0.18%	91
2023 Q1	–	Sell	-4,339	Closed	-$449K	–	265
2022 Q4	$449K	Buy	+4,339	New	+$407K	0.06%	179

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marex Group's BMRN Position: Q2 2026 in Review

Marex Group opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 4,823 shares worth $276K. The stake represents ﹤0.01% of the portfolio and ranks #894 among its holdings. This is a return to the name: Marex Group previously reported a position in BMRN as recently as Q4 2025.

Marex Group first reported a position in BMRN in Q4 2022 and has held it in 9 quarters since. The position peaked at $4.42M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Marex Group held 4,823 shares of BioMarin Pharmaceuticals worth $276K as of Q2 2026.
BioMarin Pharmaceuticals was a new Marex Group position in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #894 holding.
Marex Group first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 9 quarters since.
Marex Group's BioMarin Pharmaceuticals position peaked at $4.42M in Q4 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.